Izrael - hebrejski - Ministry of Health

bioavenir ltd - losartan as potassium 100 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin

Izrael - hebrejski - Ministry of Health

bioavenir ltd - pravastatin sodium 40 mg - tablets - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

Izrael - hebrejski - Ministry of Health

unipharm ltd, israel - roxithromycin - טבליה - roxithromycin 150 mg - roxithromycin - roxithromycin - for the treatment of infections caused by microorganisms sensitive to roxithromycin e.g: ent bronchopulmonary, genital and skin manifestations.

Izrael - hebrejski - Ministry of Health

novartis israel ltd - tobramycin - טיפות עיניים - tobramycin 0.3 % - tobramycin - tobramycin - antibiotic for the treatment of superficial eye infections caused by bacteria sensitive to tobramycin.

Izrael - hebrejski - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - טבליות מצופות פילם - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections: respiratory infections: bronchitis: acute exacerbation of chronic bronchitis ; pneumonia: community acquired ; sinusitis: acute uncomplicated; community-acquired spontaneous and wound infections of the skin and skin structure.

Izrael - hebrejski - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - טבליות מצופות פילם - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections: respiratory infections: bronchitis: acute exacerbation of chronic bronchitis ; pneumonia: community acquired ; sinusitis: acute uncomplicated; community-acquired spontaneous and wound infections of the skin and skin structure.

Izrael - hebrejski - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - תמיסה לאינפוזיה - moxifloxacin as hydrochloride 1.6 mg/ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.

Izrael - hebrejski - Ministry of Health

gilead sciences israel ltd - efavirenz; emtricitabine; tenofovir disoproxil as - טבליות מצופות פילם - tenofovir disoproxil as 245 mg; emtricitabine 200 mg; efavirenz 600 mg - tenofovir disoproxil - tenofovir disoproxil - atripla is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults.

Izrael - hebrejski - Ministry of Health

j-c health care ltd - rilpivirine as hydrochloride - טבליה - rilpivirine as hydrochloride 25 mg - rilpivirine - rilpivirine - edurant in combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-na?ve adult patients.

Izrael - hebrejski - Ministry of Health

salomon,levin & elstein ltd - gemcitabine as hydrochloride 200 mg/vial - powder for solution for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.